Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 173

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 173
---
ilution Adjustment, which registration statement we agree to use our commercially reasonable efforts to become effective; (b) the Stockholder Approval Notice Date; and (c) the effective date of the filingof the Certificate of Amendment. If a reverse stock split is effected an additional 3,156,312 (on a pre-reverse split basis which number shall be adjusted based on the reverse stock split ratio) shares of Common Stock will be issuable upon exercise of the May 2025 Warrants and then, subject to obtaining Warrant Stockholder Approval, if a subsequent offering occurs for which the exercise price of the May 2025 Warrants is reset to the floor price of $0.10 per share, an additional 61,397,642 (on a pre-reverse split basis which number shall be adjusted based on the reverse stock split ratio) shares of Common Stock would be issuable upon exercise of the May 2025 Warrants. Those purchasers who do not enter into the Purchase Agreement and do not provide us with information required for registration of the resale of shares of Common Stock shall not have any of their shares issuable as a result of an Anti-Dilution Adjustment included in the registration statement we will file covering shares issuable as a result of an Anti-Dilution Adjustment and will not be able to effect a cashless exercise with respect to such shares

Exercisability

The May 2025 Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser prior to the issuance of the May 2025 Warrants, 9.99%) of the outstanding Common Stock immediately after exercise. Following the issuance of the May 2025 Warrants, upon notice from the holder to us, the holder may increase or decrease the amount of beneficial ownership of outstanding stock after exercising the holder’s warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the May 2025 Warrants and in accordance with the rules and regulations of the SEC,